OTCM
SSKN
Market cap23kUSD
Sep 11, Last price
0.01USD
1D
0.00%
1Q
-95.87%
Jan 2017
-99.98%
IPO
-100.00%
Name
STRATA Skin Sciences Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
STRATA Skin Sciences, Inc. is an innovative medical technology enterprise dedicated to the development, commercialization, and marketing of advanced products specifically designed for treating a range of dermatologic conditions. The company operates through two main divisions: Dermatology Recurring Procedures and Dermatology Procedures Equipment. With a substantial global footprint, STRATA Skin Sciences distributes its solutions across the United States, Europe, the Middle East, Asia, Australia, South Africa, and both Central and South America. Its notable product portfolio includes the XTRAC and Pharos excimer laser systems, VTRAC lamp systems, and TheraClear treatment solutions. These technologies are instrumental in addressing common skin ailments such as psoriasis, vitiligo, and acne, among others. Domestically, the company engages directly with physicians for product distribution, while leveraging a network of international distributors to reach markets beyond the U.S. Established in 1989 and headquartered in Horsham, Pennsylvania, the company adopted its current name, STRATA Skin Sciences, Inc., in January 2016, having previously operated as MELA Sciences, Inc.
Key people
LuAnn Via
Chairman of the Board · since 2017
Michael R. Stewart
President, Chief Executive Officer, Director · since 2014
Dolev Rafaeli
Interim Chief Executive Officer · since 2018
Matthew C. Hill
Chief Financial Officer · since 2018
James L Coyne
Director · since 2017
Frank J. McCaney
President, Director · since 2018
Independent Director · since 2014
David K. Stone
Independent Director · since 2013
Kathryn B. Swintek
Independent Director · since 2013
IPO date
Oct 28, 2005
Employees
114
Domiciled in
US
Incorporated in
US
Legal address
c/o UNITED CORPORATE SERVICES, INC., 874 WALKER RD STE C
Dover, DE 19904
US
Dover, DE 19904
US
Headquarters
5 Walnut Grove Drive, Ste. 140
Horsham, PA 19044
US
Horsham, PA 19044
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||